Mid career · publishing since 2002Rising activity
Prostate Cancer Treatment and ResearchCancer, Lipids, and MetabolismBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersProstate Cancer Diagnosis and Treatment
Publications
61
Citations
627
Est. group size
~3
Recurring co-author estimate
Active years
25
Publishing since 2002
In context
Among 4,491 mid career Medicine PIs within our index
Citations: 627p25 240 · p75 1,552 · cohort median 614
Publications / year (recent): 7.6p25 1.8 · p75 7.2 · cohort median 3.4
Typically publishes in teams of ~13 · 3% small-team papers (≤3 authors) · across 10 venues
Publication cadence
Publications per year over the last 10 years — averaging 7.6/year recently
Recent publications
- Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI)
Clinical Genitourinary Cancer · 2026
- <i>SPOP</i> Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer
The Prostate · 2026
- Clinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology · 2026
- Profiling of exceptional responders (ER) and non-responders (NR) to androgen receptor pathway inhibitors (ARPI) in men with metastatic hormone sensitive and castration resistant prostate cancer.
Journal of Clinical Oncology · 2025
- Outcomes for patients with SPOP-mutated castration-resistant prostate cancer (CRPC) treated with an androgen receptor pathway inhibitor (ARPI).
Journal of Clinical Oncology · 2025
- <i>SPOP</i> mutations in veterans with metastatic castration-resistant prostate cancer (mCRPC) and the association with race and response to an androgen receptor pathway inhibitor (ARPI).
Journal of Clinical Oncology · 2025
- The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
Clinical Cancer Research · 2024
- Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer
Advances in Oncology · 2024
- Supplementary Figure S1 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2024
- Supplementary Table S2 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2024
- Supplementary Table S3 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2024
- Supplementary Figure S1 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2024
- Supplementary Table S1 from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2024
- Data from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2024
- Data from The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
2024
Publishes in
- Journal of Clinical Oncology×14
- Clinical Genitourinary Cancer×5
- JCO Precision Oncology×3
- Prostate Cancer and Prostatic Diseases×2
- British Journal of Urology×2
Similar researchers
By research-topic overlap
- Dinuka De Silva
Medicine · Indiana University
- Paul Monk
Medicine · The Ohio State University
- Martin Gleave
Medicine · University of Michigan
- Joshi J. Alumkal
Medicine · University of Michigan
- Jennifer A. Sinnott
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile